Hi-Res HER2 Test

[cs_content][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 45px 0px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/3″ style=”padding: 0px;”][x_image type=”circle” src=”http://targeted-genomics.com/wp-content/uploads/2018/04/Artboard-3her2.png” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=””][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”2/3″ style=”padding: 0px;”][x_custom_headline level=”h1″ looks_like=”h2″ accent=”false”]High Resolution (Hi-Res) HER2 Testing for HER2 Equivocal Breast Cancer[/x_custom_headline][/cs_column][/cs_row][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 50px auto 0px;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ class=”cs-ta-center” style=”padding: 0px;”][x_image type=”none” src=”http://targeted-genomics.com/wp-content/uploads/2016/05/breasttissue2.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=”” id=”imagepush”][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][cs_text]Knowing the HER2 (ERBB2) status in newly diagnosed breast cancer is critical for selecting patients predicted to respond to anti-HER2 therapy.

The College of American Pathologists (CAP)/American Society for Clinical Oncology (ASCO) guidelines recommend all newly diagnosed and metastatic breast tumors be evaluated for HER2 positivity by protein-based immunohistochemistry (IHC) and/or chromosome-based fluorescence in situhybridization (FISH) .

In the majority of cases, these tests provide a clearly actionable “positive” or “negative” answer.[/cs_text][/cs_column][/cs_row][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ style=”padding: 0px;”][cs_text]However, in an estimated 10- to 20% of breast cancers the tumor’s true HER2 status remains a mystery because both tests are reported as “equivocal.”

“Double equivocal” breast cancer presents a treatment decision dilemma for oncologists and the clinical need for an alternative testing method to deliver unequivocal results.

The Hi-Res HER2 test is designed to meet the needs of oncologists and their patients with “high-risk, HER2 equivocal breast cancer.”

Drawing from over 10 years experience in resolving “double equivocal” breast cancer, the Hi-Res HER2 test was developed by Targeted Genomics and optimized in the PacificDxLaboratory, Irvine CA to provide the answers clinicians and patients are looking for.[/cs_text][/cs_column][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/2″ class=”cs-ta-center” style=”padding: 0px;”][x_image type=”none” src=”http://targeted-genomics.com/wp-content/uploads/2016/05/breasttissue1.jpg” alt=”” link=”false” href=”#” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=”” id=”imagepush”][/cs_column][/cs_row][/cs_section][cs_section bg_color=”hsl(0, 0%, 60%)” parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: -30px 0px 0px;padding: 0px 0px 25px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ style=”padding: 0px;”][cs_text]

Hi-Res HER2 uses DNA microarray to provide:

• Definitive results for HER2 gene status.
• Results from formalin fixed paraffin embedded (FFPE) tissue.
• Fast turn around time
• Testing billable to insurance

[/cs_text][/cs_column][/cs_row][/cs_section][cs_section parallax=”false” separator_top_type=”none” separator_top_height=”50px” separator_top_angle_point=”50″ separator_bottom_type=”none” separator_bottom_height=”50px” separator_bottom_angle_point=”50″ style=”margin: 0px;padding: 0px 0px 45px;”][cs_row inner_container=”true” marginless_columns=”false” style=”margin: 0px auto;padding: 0px;”][cs_column fade=”false” fade_animation=”in” fade_animation_offset=”45px” fade_duration=”750″ type=”1/1″ class=”cs-ta-center orderDiv” style=”padding: 0px;”][cs_text]

For Hi-Res HER2 consultations please contact Precision Pathology Client Services: 210-646-0890.

[/cs_text][x_button shape=”pill” size=”global” block=”false” circle=”false” icon_only=”false” href=”/contact-us/” title=”” target=”” info=”none” info_place=”top” info_trigger=”hover” info_content=”” id=”orderButton” style=”padding-top: 18px;background-color: #F1008C;”]Contact us[/x_button][cs_text][printfriendly][/cs_text][/cs_column][/cs_row][/cs_section][/cs_content]